MedTrace Logo

A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)

NCT01408615 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 472

Last updated 2022-02-03

No results posted yet for this study

Summary

This observational study will examine the safety and efficacy profile of Elonva (corifollitropin alfa) when administered in Korean women undergoing controlled ovarian stimulation (COS) in combination with a gonadotropin-releasing hormone (GnRH) antagonist for the development of multiple follicles in an assisted reproductive technology (ART) program.

Conditions

  • Infertility, Female

Interventions

DRUG

corifollitropin alfa

100 or 150 microgram single subcutaneous injection

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-20
Primary Completion
2016-11-18
Completion
2016-11-18

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408615 on ClinicalTrials.gov